AU2006207987B2 - Methods for treating renal cell carcinoma - Google Patents
Methods for treating renal cell carcinoma Download PDFInfo
- Publication number
- AU2006207987B2 AU2006207987B2 AU2006207987A AU2006207987A AU2006207987B2 AU 2006207987 B2 AU2006207987 B2 AU 2006207987B2 AU 2006207987 A AU2006207987 A AU 2006207987A AU 2006207987 A AU2006207987 A AU 2006207987A AU 2006207987 B2 AU2006207987 B2 AU 2006207987B2
- Authority
- AU
- Australia
- Prior art keywords
- des
- patients
- sequence
- treatment
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 83
- 208000006265 Renal cell carcinoma Diseases 0.000 title abstract description 26
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 277
- 230000000694 effects Effects 0.000 claims abstract description 27
- 230000001771 impaired effect Effects 0.000 claims abstract description 24
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims description 70
- 230000004044 response Effects 0.000 claims description 60
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 230000036961 partial effect Effects 0.000 claims description 23
- 108700025316 aldesleukin Proteins 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims description 10
- 229960005310 aldesleukin Drugs 0.000 claims description 9
- 150000002314 glycerols Polymers 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Polymers OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- FBPFZTCFMRRESA-NQAPHZHOSA-N Sorbitol Polymers OCC(O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-NQAPHZHOSA-N 0.000 claims description 2
- 150000002303 glucose derivatives Polymers 0.000 claims description 2
- 150000002304 glucoses Polymers 0.000 claims description 2
- 125000002791 glucosyl group Polymers C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 26
- 231100000419 toxicity Toxicity 0.000 abstract description 12
- 230000001988 toxicity Effects 0.000 abstract description 12
- 230000002411 adverse Effects 0.000 abstract description 10
- 230000002829 reductive effect Effects 0.000 abstract description 9
- 230000004614 tumor growth Effects 0.000 abstract description 5
- 238000011285 therapeutic regimen Methods 0.000 abstract description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 273
- 239000000203 mixture Substances 0.000 description 52
- 108090000765 processed proteins & peptides Proteins 0.000 description 52
- 102000004196 processed proteins & peptides Human genes 0.000 description 49
- 229920001184 polypeptide Polymers 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 30
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 29
- 201000010099 disease Diseases 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 239000008194 pharmaceutical composition Substances 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 26
- 125000003275 alpha amino acid group Chemical group 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 25
- 230000003902 lesion Effects 0.000 description 25
- 230000004083 survival effect Effects 0.000 description 25
- 239000002243 precursor Substances 0.000 description 24
- 238000006467 substitution reaction Methods 0.000 description 23
- 229940087463 proleukin Drugs 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 238000009472 formulation Methods 0.000 description 17
- 238000013059 nephrectomy Methods 0.000 description 16
- 239000007788 liquid Substances 0.000 description 14
- 125000000539 amino acid group Chemical group 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 206010062237 Renal impairment Diseases 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 231100000857 poor renal function Toxicity 0.000 description 11
- 150000003839 salts Chemical group 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000003907 kidney function Effects 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 229930182817 methionine Natural products 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 235000004279 alanine Nutrition 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 101150004094 PRO2 gene Proteins 0.000 description 6
- 102220589633 RING finger protein 37_L40R_mutation Human genes 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000004797 therapeutic response Effects 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 102000011923 Thyrotropin Human genes 0.000 description 5
- 108010061174 Thyrotropin Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
- 231100000417 nephrotoxicity Toxicity 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 208000037821 progressive disease Diseases 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- 235000014393 valine Nutrition 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000006172 buffering agent Substances 0.000 description 4
- 239000004067 bulking agent Substances 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 230000007694 nephrotoxicity Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 102220497102 5-hydroxytryptamine receptor 3B_P65V_mutation Human genes 0.000 description 3
- 102220504866 Aladin_L40S_mutation Human genes 0.000 description 3
- 102220619065 Alpha-1,3-galactosyltransferase 2_R81E_mutation Human genes 0.000 description 3
- 102220465452 Angiogenin_K64Q_mutation Human genes 0.000 description 3
- 102220624991 Bcl-2-like protein 2_H79N_mutation Human genes 0.000 description 3
- 102220638992 Beta-enolase_H16D_mutation Human genes 0.000 description 3
- 102220638985 Beta-enolase_H16E_mutation Human genes 0.000 description 3
- 102220595179 Casein kinase II subunit alpha'-interacting protein_F78W_mutation Human genes 0.000 description 3
- 241001227713 Chiron Species 0.000 description 3
- 102220603939 Clathrin heavy chain 1_P65N_mutation Human genes 0.000 description 3
- 108700004922 F42A Proteins 0.000 description 3
- 102220630762 Fibrinogen alpha chain_R38N_mutation Human genes 0.000 description 3
- 102220630764 Fibrinogen alpha chain_R38S_mutation Human genes 0.000 description 3
- 102220597417 Fizzy-related protein homolog_R81L_mutation Human genes 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 102220571087 Growth arrest and DNA damage-inducible protein GADD45 gamma_L80E_mutation Human genes 0.000 description 3
- 101001127203 Homo sapiens 60S ribosomal protein L36a Proteins 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 102220524218 Interferon regulatory factor 6_N88H_mutation Human genes 0.000 description 3
- 102220511586 Kappa-casein_D84R_mutation Human genes 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102220617354 Leucine-rich repeat-containing protein 34_V91W_mutation Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102220548801 Mitochondrial import inner membrane translocase subunit TIM16_L94A_mutation Human genes 0.000 description 3
- 102220570925 N-acetylgalactosamine-6-sulfatase_L36P_mutation Human genes 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010029155 Nephropathy toxic Diseases 0.000 description 3
- 102220602029 Neutrophil elastase_R81P_mutation Human genes 0.000 description 3
- 102220546836 Nuclear pore complex protein Nup85_L19D_mutation Human genes 0.000 description 3
- 102220624881 PDZ and LIM domain protein 2_L80K_mutation Human genes 0.000 description 3
- 102220529451 Phorbol-12-myristate-13-acetate-induced protein 1_L36E_mutation Human genes 0.000 description 3
- 102220552473 Platelet-activating factor acetylhydrolase_K64D_mutation Human genes 0.000 description 3
- 102220527093 Polycomb group RING finger protein 2_P65S_mutation Human genes 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 102220550572 Proteasome maturation protein_L19E_mutation Human genes 0.000 description 3
- 102220471703 Proteasome subunit alpha type-7_K32A_mutation Human genes 0.000 description 3
- 102220471792 Proteasome subunit alpha type-7_L36A_mutation Human genes 0.000 description 3
- 102220511395 Proteasome subunit beta type-10_K35T_mutation Human genes 0.000 description 3
- 102220519967 Protein DEK_L66A_mutation Human genes 0.000 description 3
- 102220538345 Putative stereocilin-like protein_K35M_mutation Human genes 0.000 description 3
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 description 3
- 102220471503 Replication factor C subunit 4_R38D_mutation Human genes 0.000 description 3
- 102220547809 Serine/threonine-protein kinase B-raf_N88T_mutation Human genes 0.000 description 3
- 102220560185 Stromal cell-derived factor 1_K64R_mutation Human genes 0.000 description 3
- 102220500923 Telomerase reverse transcriptase_K35D_mutation Human genes 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 102220618307 YLP motif-containing protein 1_F42E_mutation Human genes 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 102220345545 c.103A>C Human genes 0.000 description 3
- 102220431680 c.124T>G Human genes 0.000 description 3
- 102220350876 c.190A>G Human genes 0.000 description 3
- 102220420188 c.193C>A Human genes 0.000 description 3
- 102220359607 c.194C>A Human genes 0.000 description 3
- 102220349468 c.194C>T Human genes 0.000 description 3
- 102220427208 c.233T>C Human genes 0.000 description 3
- 102220353454 c.262A>G Human genes 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000027950 fever generation Effects 0.000 description 3
- -1 for example Chemical class 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102220004796 rs104893939 Human genes 0.000 description 3
- 102220223535 rs1060501767 Human genes 0.000 description 3
- 102220223852 rs1060502978 Human genes 0.000 description 3
- 102200026593 rs1065852 Human genes 0.000 description 3
- 102220234588 rs1114167484 Human genes 0.000 description 3
- 102220234204 rs1114167734 Human genes 0.000 description 3
- 102220110995 rs115116507 Human genes 0.000 description 3
- 102200081185 rs121909273 Human genes 0.000 description 3
- 102200042537 rs121909608 Human genes 0.000 description 3
- 102200115315 rs121918084 Human genes 0.000 description 3
- 102220320766 rs1554448978 Human genes 0.000 description 3
- 102200066678 rs1554618767 Human genes 0.000 description 3
- 102220322294 rs1554831400 Human genes 0.000 description 3
- 102220242995 rs1555187010 Human genes 0.000 description 3
- 102220266103 rs199901239 Human genes 0.000 description 3
- 102200136470 rs35114462 Human genes 0.000 description 3
- 102220056637 rs730880955 Human genes 0.000 description 3
- 102200080011 rs755832705 Human genes 0.000 description 3
- 102220097736 rs774586397 Human genes 0.000 description 3
- 102220062242 rs786201968 Human genes 0.000 description 3
- 102200076864 rs869312138 Human genes 0.000 description 3
- 102220098003 rs876661384 Human genes 0.000 description 3
- 238000010845 search algorithm Methods 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000030939 Bubalus bubalis Species 0.000 description 2
- 101100049641 Caenorhabditis elegans pfs-2 gene Proteins 0.000 description 2
- 241000282556 Cercocebus atys Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102220581530 DNA dC->dU-editing enzyme APOBEC-3G_E67A_mutation Human genes 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102220515709 Interferon regulatory factor 8_R81K_mutation Human genes 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000283128 Mirounga angustirostris Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 2
- 241000699667 Mus spretus Species 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 102220592496 Non-homologous end-joining factor 1_Q11A_mutation Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283283 Orcinus orca Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000282516 Papio anubis Species 0.000 description 2
- 108010043958 Peptoids Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920000037 Polyproline Polymers 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102220610852 Thialysine N-epsilon-acetyltransferase_L72G_mutation Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 102220370481 c.101C>G Human genes 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 102000055277 human IL2 Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000007434 lytic lesion Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 108010026466 polyproline Proteins 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220234844 rs1131690927 Human genes 0.000 description 2
- 102200000390 rs121917859 Human genes 0.000 description 2
- 102200158049 rs387906619 Human genes 0.000 description 2
- 102220250393 rs553900705 Human genes 0.000 description 2
- 102220058220 rs730881937 Human genes 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100060192 Anopheles gambiae ser4 gene Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 101100119767 Caenorhabditis elegans fat-4 gene Proteins 0.000 description 1
- 101100468762 Caenorhabditis elegans ric-3 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101001002613 Canis lupus familiaris Interleukin-2 Proteins 0.000 description 1
- 201000005488 Capillary Leak Syndrome Diseases 0.000 description 1
- 241000008374 Capirona Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000283705 Capra hircus Species 0.000 description 1
- 241000282985 Cervus Species 0.000 description 1
- 241000283026 Cervus elaphus Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000484025 Cuniculus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101001002658 Equus caballus Interleukin-2 Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000699696 Meriones Species 0.000 description 1
- 241000699684 Meriones unguiculatus Species 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108010049175 N-substituted Glycines Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 101001043815 Ovis aries Interleukin-2 Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101001043830 Rattus norvegicus Interleukin-2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000282696 Saimiri sciureus Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 101001043834 Sus scrofa Interleukin-2 Proteins 0.000 description 1
- 208000031932 Systemic capillary leak syndrome Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010045169 Tumour flare Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- PNVLWFYAPWAQMU-CIUDSAMLSA-N Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)C(C)C PNVLWFYAPWAQMU-CIUDSAMLSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical group N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 231100001156 grade 3 toxicity Toxicity 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007409 radiographic assessment Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102220097967 rs876660873 Human genes 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012883 sequential measurement Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229950001699 teceleukin Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64749605P | 2005-01-27 | 2005-01-27 | |
| US60/647,496 | 2005-01-27 | ||
| PCT/US2006/003116 WO2006081510A2 (en) | 2005-01-27 | 2006-01-27 | Methods for treating renal cell carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2006207987A1 AU2006207987A1 (en) | 2006-08-03 |
| AU2006207987B2 true AU2006207987B2 (en) | 2011-09-15 |
Family
ID=36741121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006207987A Ceased AU2006207987B2 (en) | 2005-01-27 | 2006-01-27 | Methods for treating renal cell carcinoma |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20070014765A1 (https=) |
| EP (1) | EP1846020B1 (https=) |
| JP (2) | JP2008528621A (https=) |
| KR (1) | KR20070102576A (https=) |
| CN (1) | CN101132809A (https=) |
| AU (1) | AU2006207987B2 (https=) |
| BR (1) | BRPI0606774A2 (https=) |
| CA (1) | CA2595959A1 (https=) |
| ES (1) | ES2432141T3 (https=) |
| IL (1) | IL184865A (https=) |
| MX (1) | MX2007009012A (https=) |
| RU (1) | RU2404795C2 (https=) |
| WO (1) | WO2006081510A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110243851A1 (en) | 2008-12-11 | 2011-10-06 | Agency For Science, Technology And Research | Glucose-peg conjugates for reducing glucose transport into a cell |
| US20150299255A1 (en) * | 2010-11-01 | 2015-10-22 | Susavion Biosciences, Inc. | Compositions and methods for modulating innate and adaptive immune systems |
| CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| DK2683395T3 (en) * | 2011-03-11 | 2018-11-19 | Hopitaux Paris Assist Publique | USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES |
| BR112013023151A2 (pt) * | 2011-03-11 | 2020-09-15 | Assistance Publique - Hôpitaux De Paris | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| AU2015301936B2 (en) | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| US10350260B2 (en) * | 2015-04-27 | 2019-07-16 | Susavion Biosciences, Inc. | Compositions and methods for treating cancer and persistent viral infections |
| JP6740250B2 (ja) * | 2015-04-27 | 2020-08-12 | スサヴィオン バイオサイエンシーズ インコーポレイテッド | がんおよび持続性ウイルス感染を処置するための組成物および方法 |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| MY206158A (en) | 2017-05-24 | 2024-12-02 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CN111201035A (zh) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
| JP7325341B2 (ja) | 2017-07-11 | 2023-08-14 | シンソークス，インク． | 非天然ヌクレオチドの組み込み及びその方法 |
| KR20240141853A (ko) | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| KR102777151B1 (ko) * | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| SG11202102930YA (en) | 2018-11-08 | 2021-04-29 | Synthorx Inc | Interleukin 10 conjugates and uses thereof |
| EP3923974A4 (en) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | IL-2 CONJUGATES AND METHODS OF USE THEREOF |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| EP4017540A1 (en) | 2019-08-23 | 2022-06-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| US12234271B2 (en) | 2019-09-10 | 2025-02-25 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| WO2021127487A2 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004002526A1 (en) * | 2002-07-01 | 2004-01-08 | Wilex Ag | Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4752585A (en) * | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4931543A (en) | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
| ES2264145T3 (es) * | 1995-11-30 | 2006-12-16 | The Board Of Regents, The University Of Texas System | Metodos y composiciones para el tratamiento de cancer. |
-
2006
- 2006-01-27 JP JP2007553304A patent/JP2008528621A/ja active Pending
- 2006-01-27 EP EP06719806.9A patent/EP1846020B1/en not_active Expired - Lifetime
- 2006-01-27 BR BRPI0606774-3A patent/BRPI0606774A2/pt not_active Application Discontinuation
- 2006-01-27 CA CA002595959A patent/CA2595959A1/en not_active Abandoned
- 2006-01-27 MX MX2007009012A patent/MX2007009012A/es active IP Right Grant
- 2006-01-27 ES ES06719806T patent/ES2432141T3/es not_active Expired - Lifetime
- 2006-01-27 AU AU2006207987A patent/AU2006207987B2/en not_active Ceased
- 2006-01-27 KR KR1020077019556A patent/KR20070102576A/ko not_active Ceased
- 2006-01-27 US US11/342,243 patent/US20070014765A1/en not_active Abandoned
- 2006-01-27 RU RU2007132125/14A patent/RU2404795C2/ru not_active IP Right Cessation
- 2006-01-27 WO PCT/US2006/003116 patent/WO2006081510A2/en not_active Ceased
- 2006-01-27 CN CNA2006800067217A patent/CN101132809A/zh active Pending
-
2007
- 2007-07-26 IL IL184865A patent/IL184865A/en active IP Right Grant
-
2009
- 2009-07-28 US US12/460,991 patent/US8012465B2/en not_active Expired - Fee Related
-
2011
- 2011-12-06 JP JP2011266809A patent/JP2012046552A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004002526A1 (en) * | 2002-07-01 | 2004-01-08 | Wilex Ag | Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
Non-Patent Citations (2)
| Title |
|---|
| Amato et al. Proc Am. Assoc. Clin. Oncol. (2003) vol. 22, abstract 1556 * |
| Sleijfer et al. Journal of Clinical Oncology (1992) vol. 10, no. 7, pages 1119-1123 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20070014765A1 (en) | 2007-01-18 |
| CA2595959A1 (en) | 2006-08-03 |
| IL184865A (en) | 2011-04-28 |
| RU2007132125A (ru) | 2009-03-10 |
| KR20070102576A (ko) | 2007-10-18 |
| MX2007009012A (es) | 2007-09-14 |
| IL184865A0 (en) | 2007-12-03 |
| ES2432141T3 (es) | 2013-11-29 |
| WO2006081510A2 (en) | 2006-08-03 |
| RU2404795C2 (ru) | 2010-11-27 |
| JP2012046552A (ja) | 2012-03-08 |
| EP1846020A2 (en) | 2007-10-24 |
| JP2008528621A (ja) | 2008-07-31 |
| US8012465B2 (en) | 2011-09-06 |
| WO2006081510A3 (en) | 2007-01-18 |
| EP1846020B1 (en) | 2013-08-21 |
| CN101132809A (zh) | 2008-02-27 |
| BRPI0606774A2 (pt) | 2009-07-14 |
| US20100316595A1 (en) | 2010-12-16 |
| AU2006207987A1 (en) | 2006-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006207987B2 (en) | Methods for treating renal cell carcinoma | |
| JP6718494B2 (ja) | 癌を処置するためのペグ化ｉｌ−１０の使用 | |
| EP1220682B1 (en) | Stabilized liquid polypeptide-containing pharmaceutical compositions | |
| CN111093688B (zh) | 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法 | |
| JP2023099731A (ja) | ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用 | |
| KR20070108402A (ko) | 화학요법제와 ｉｌ-2 및 선택적으로 항-ｃｄ20 항체의조합물을 사용하여 임파종을 치료하는 방법 | |
| US20060039892A1 (en) | Methods of healing wounds by administering human IL-18 | |
| HK1253347B (en) | Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |